Cardiology 2013

Notes: Anker, Markus S

von Haehling, Stephan

Springer, Jochen

Banach, Maciej

Anker, Stefan D

eng

Review

Poland

2013/03/22 06:00

Arch Med Sci. 2013 Feb 21;9(1):166-71. doi: 10.5114/aoms.2013.33356.

URL: http://www.ncbi.nlm.nih.gov/pubmed/23515589

Author Address: Center for Clinical and Basic Research, IRCCS San Raffaele, Rome, Italy.

 

 

Reference Type:  Journal Article

Record Number: 823Author: Anker, M. S., von Haehling, S., Springer, J., Banach, M. and Anker, S. D.

Year: 2013

Title: Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology

Journal: Int J Cardiol

Volume: 162

Issue: 2

Pages: 73-6

Date: Jan 10

Short Title: Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology

Alternate Journal: International journal of cardiology

ISSN: 1874-1754 (Electronic)

0167-5273 (Linking)

DOI: 10.1016/j.ijcard.2012.10.018

Accession Number: 23174169

Keywords: Biomedical Research

Cachexia/*drug therapy/*physiopathology

Cardiovascular Diseases/drug therapy/physiopathology

Ghrelin/therapeutic use

Humans

Lipolysis/physiology

Muscular Atrophy/physiopathology

Sarcopenia/*drug therapy/*physiopathology

Abstract: Sarcopenia and cachexia are significant medical problems with a high disease related burden in cardiovascular illness. Muscle wasting and weight loss are very frequent particularly in chronic heart failure and they relate to poor prognosis. Although clinically largely underestimated, the fields of cachexia and sarcopenia are of great relevance to cardiologists. In cachexia and sarcopenia a significant number of research publications related to basic science questions of muscle wasting and lipolysis were published between 2010 and 2012. Recently, the two processes of muscle wasting and lipolysis were found to be closely linked. Treatment research in pre-clinical models involves studies on a number of different therapeutic entities, including ghrelin, selective androgen receptor modulators (SARMs), as well as drugs targeting myostatin or melanocortin-4. In the human setting, studies using enobosarm (a SARM) and anamorelin (ghrelin) are in phase III. The last 3 years has seen significant efforts to define the field using consensus statements. In the future, these definitions should also be considered for guidelines and treatment trials in cardiovascular medicine. The current review aims to summarize important information and development in the fields of muscle wasting, sarcopenia and cachexia focussing on findings in cardiovascular research, in order for cardiologists to have a better understanding of the progress in the still not well enough known field.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208